{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:24Z","timestamp":1753891884434,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"Background<\/jats:title>Current first-line anti-proteinuric treatments do not produce a satisfactory therapeutic effect in a considerable number of patients with nephrotic syndrome (NS). Interest in adrenocorticotropic hormone (ACTH) for the treatment of NS has recently been revived. The present study investigated the efficacy and safety of ACTH treatment in children with frequent relapsing NS (FRNS), steroid-dependent NS (SDNS), and steroid-resistant NS (SRNS).<\/jats:p><\/jats:sec>Method<\/jats:title>The ACTH treatment group was comprised of NS patients receiving ACTH treatment. Patients with serum cortisol concentrations &lt;85.3\u2005nmol\/L and who had not received ACTH treatment previously were enrolled in the control group from January 2018 to January 2021. The maintenance dose of prednisone, the number of disease recurrences, the time of first disease relapse, immunosuppressant use, serum cortisol levels, and adverse events were recorded in both groups.<\/jats:p><\/jats:sec>Results<\/jats:title>Fifty-one patients were included in the ACTH group, and twenty-one patients were enrolled in the control group. Concurrent treatment with one or more immunosuppressive and\/or cytotoxic treatments occurred in 92.2% and 85.7% of patients in the ACTH and control groups, respectively, throughout the study period. A greater reduction in the prednisone maintenance dose was observed in the ACTH group compared with the control group after 1 year of follow up (0.603\u2009\u00b1\u20090.445\u2005mg\/kg vs. 0.267\u2009\u00b1\u20090.500\u2005mg\/kg, p<\/jats:italic>\u2009=\u20090.006). During the one-year study period, fewer participants experienced one or more disease relapses in the ACTH group (45.1%) compared to the control group (76.2%, odds ratio\u2009=\u20093.896, p<\/jats:italic>\u2009=\u20090.016). The number of disease recurrences per patient in the ACTH group was less than that in the control group (median difference\u2009=\u2009\u22121, p<\/jats:italic>\u2009=\u20090.006). The mean length of remission was 8.902\u2005m and 7.905\u2005m in the ACTH group and control group, respectively. A log-rank test showed a longer relapse free survival for patients in the ACTH group (p<\/jats:italic>\u2009=\u20090.046), but the Breslow test showed no significant difference between groups (p<\/jats:italic>\u2009=\u20090.104). Ten patients in the ACTH group successfully discontinued all drug therapies. No patients in the control group were able to discontinue drug therapy as of February 2022.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>ACTH, combined with multiple drugs, is effective at reducing the prednisone maintenance dose and may effectively prevent disease relapses in childhood NS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1044075","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T07:12:25Z","timestamp":1678345945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-word adrenocorticotropic hormone treatment for childhood-onset nephrotic syndrome"],"prefix":"10.3389","volume":"11","author":[{"given":"Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiqiang","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingnan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1007\/s00467-016-3509-z","article-title":"Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic?","volume":"31","author":"Dossier","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","article-title":"IPNA Clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome","volume":"35","author":"Trautmann","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00467-021-05175-9","article-title":"Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: the BELNEPH study","volume":"37","author":"Vivarelli","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00467-012-2310-x","article-title":"Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO","volume":"28","author":"Lombel","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.2215\/CJN.06890618","article-title":"Adrenocorticotropic hormone for childhood nephrotic syndrome","volume":"13","author":"Wang","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B6","first-page":"630","article-title":"The management of the nephrotic syndrome","volume":"28","author":"Riley","year":"1952","journal-title":"Bull N Y Acad Med"},{"key":"B7","first-page":"959","article-title":"Treatment of the nephrotic syndrome in children","volume":"73","author":"Rance","year":"1955","journal-title":"Can Med Assoc J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nrneph.2011.190","article-title":"The renaissance of corticotropin therapy in proteinuric nephropathies","volume":"8","author":"Gong","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40620-016-0308-3","article-title":"Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance","volume":"30","author":"Lieberman","year":"2016","journal-title":"J Nephrol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12882-016-0241-7","article-title":"Acthar Gel in the treatment of nephrotic syndrome: a multicenter retrospective case series","volume":"17","author":"Madan","year":"2016","journal-title":"BMC Nephrol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1159\/000506854","article-title":"Relapse of nephrotic syndrome after adrenocorticotropic hormone-induced remission: implications of adrenocorticotropic hormone antibodies","volume":"51","author":"Shrivastava","year":"2020","journal-title":"Am J Nephrol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e20162169","DOI":"10.1542\/peds.2016-2169","article-title":"Acquired resistance to corticotropin therapy in nephrotic syndrome: role of de novo neutralizing antibody","volume":"140","author":"Wang","year":"2017","journal-title":"Pediatrics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12882-018-0915-4","article-title":"Use of synthetic adrenocorticotropic hormone in patients with IgA nephropathy","volume":"2319","author":"Prasad","year":"2018","journal-title":"BMC Nephrol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.ekir.2017.05.015","article-title":"Safety and efficacy of combination ACTHar gel and tacrolimus in treatment-resistant focal segmental glomerulosclerosis and membranous glomerulopathy","volume":"2","author":"Tumlin","year":"2017","journal-title":"Kidney Int Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3760\/cma.j.issn.0578-1310.2017.10.003","article-title":"Evidence based guidelines for the diagnosis and treatment of steroid sensitive, relapsing\/dependent nephrotic syndrome in children (2016)","volume":"55","year":"2017","journal-title":"Chin J Pediatrics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00467-011-2083-7","article-title":"The increasing incidence of initial steroid resistance in childhood nephrotic syndrome","volume":"27","author":"Banaszak","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"B18","first-page":"101","article-title":"A single-center, cross-sectional study of children with steroid-resistant nephrotic syndrome in southern China","volume":"1","author":"Zheng","year":"2021","journal-title":"Iran J Kidney Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2597079","DOI":"10.1155\/2020\/2597079","article-title":"ACTH Treatment for management of nephrotic syndrome: a systematic review and reappraisal","volume":"2020","author":"Chakraborty","year":"2020","journal-title":"Int J Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1749-6632.2009.04434.x","article-title":"Adrenocorticotropic hormone, melanocyte-stimulating hormone, and the melanocortin receptors: revisiting the work of Robert Schwyzer","volume":"1163","author":"Dores","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"108930","DOI":"10.1016\/j.steroids.2021.108930","article-title":"Adrenocorticotropic hormone: an expansion of our current understanding of the treatment for nephrotic syndrome","volume":"176","author":"Hu","year":"2021","journal-title":"Steroids"},{"key":"B22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ekir.2019.10.007","article-title":"An open-label pilot study of adrenocorticotrophic hormone in the treatment of IgA nephropathy at high risk of progression","volume":"5","author":"Zand","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2022050605","DOI":"10.1681\/ASN.2022050605","article-title":"Negative modulation of B cell activation by MC1R signaling protects against membranous nephropathy","author":"Chen","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.kint.2022.09.025","article-title":"Hematopoietic-specific melanocortin 1 receptor signaling protects against nephrotoxic serum nephritis and mediates the beneficial effect of melanocortin therapy","volume":"103","author":"Guan","year":"2023","journal-title":"Kidney Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.ackd.2013.09.004","article-title":"Leveraging melanocortin pathways to treat glomerular diseases","volume":"21","author":"Gong","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.metabol.2006.04.001","article-title":"The effects of adrenocorticotrophic hormone and an equivalent dose of cortisol on the serum concentrations of lipids, lipoproteins, and apolipoproteins","volume":"55","author":"Berg","year":"2006","journal-title":"Metab Clin Exp"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/ndt\/gfh110","article-title":"ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses","volume":"19","author":"Berg","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/tp.0000000000.00232.0","article-title":"ACTH Gel in resistant focal segmental glomerulosclerosis after kidney transplantation","volume":"103","author":"Alhamad","year":"2019","journal-title":"Transplantation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.kint.2019.04.018","article-title":"ACTH (Corticotrophin) therapy in resistant primary membranous nephropathy","volume":"96","author":"Bagchi","year":"2019","journal-title":"Kidney Int"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.transproceed.2019.04.052","article-title":"Adrenocorticotropic hormone in the treatment of focal segmental glomerulosclerosis following kidney transplantation","volume":"51","author":"Grafals","year":"2019","journal-title":"Transplant Proc"},{"key":"B31","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3760\/cma.j.cn101070-20190308-00174","article-title":"Clinical observation of the treatment of adrenocorticotropic hormone in children with frequently relapsing nephritic syndrome","volume":"35","author":"Han","year":"2020","journal-title":"Chin J Appl Clin Pediatr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0142033","DOI":"10.1371\/journal.pone.0142033","article-title":"Synthetic ACTH in high risk patients with idiopathic membranous nephropathy: a prospective, open label cohort study","volume":"10","author":"van de Logt","year":"2015","journal-title":"Plos One"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/ndt\/gfu069","article-title":"A pilot study to determine the dose and effectiveness of adrenocorticotropic hormone (H.P. Acthar\u00ae Gel) in nephrotic syndrome due to idiopathic membranous nephropathy","volume":"29","author":"Hladunewich","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1053\/j.ajkd.2018.12.025","article-title":"Repository corticotropin versus glucocorticoid for nephrotic syndrome: when will we see the evidence?","volume":"74","author":"Hartung","year":"2019","journal-title":"Am J Kidney Dis"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1044075\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T07:12:31Z","timestamp":1678345951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1044075\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":34,"alternative-id":["10.3389\/fped.2023.1044075"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1044075","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"article-number":"1044075"}}